The discovery and subsequent clinical introduction of antibiotics is one of the most important game-changers in the history of medicine \[[@B1-antibiotics-08-00129]\]. These drugs have saved millions of lives from infections that would previously have been fatal, and later, they allowed for the introduction of surgical interventions, organ transplantation, care of premature infants, and cancer chemotherapy \[[@B2-antibiotics-08-00129]\]. Nevertheless, the therapy of bacterial infections is becoming less and less straightforward due to the emergence of multidrug resistance (MDR) in these pathogens \[[@B3-antibiotics-08-00129]\]. Direct consequences of antibiotic resistance include delays in the onset of the appropriate (effective) antimicrobial therapy, the need to use older, more toxic antibiotics (e.g., colistin) with a disadvantageous side-effect profile, longer hospital stays, and an increasing burden on the healthcare infrastructure; overall, a decrease in the quality-of-life (QoL) and an increase in the mortality rate of the affected patients \[[@B4-antibiotics-08-00129],[@B5-antibiotics-08-00129]\]. To highlight the severity of the issue, several international declarations have been published to call governments around the globe to take action on antimicrobial resistance \[[@B6-antibiotics-08-00129],[@B7-antibiotics-08-00129],[@B8-antibiotics-08-00129],[@B9-antibiotics-08-00129]\].

Since the 1980s, pharmaceutical companies have slowly turned away from antimicrobial research and towards the drug therapy of chronic non-communicable diseases \[[@B10-antibiotics-08-00129],[@B11-antibiotics-08-00129]\]. New antimicrobials are usually used as last-resort agents in a narrow patient population, resulting in smaller profits \[[@B12-antibiotics-08-00129]\]. Additionally, drug companies are failing to keep up with the developments in global resistance levels; development of non-susceptibility to the novel antibiotics is inevitable, shortening the period of clinical usefulness of these drugs \[[@B13-antibiotics-08-00129]\]. During the last years, a number of antibiotics have received marketing authorization from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) ([Table 1](#antibiotics-08-00129-t001){ref-type="table"}) \[[@B14-antibiotics-08-00129],[@B15-antibiotics-08-00129],[@B16-antibiotics-08-00129]\].

Although the number of newly marketed antibiotics and the current state of the antimicrobial pipeline offers hope (owing to government-funded research programs and public--private partnerships, generating incentive for pharmaceutical companies), there are several pathogens where providing appropriate therapy is still a major concern \[[@B10-antibiotics-08-00129],[@B11-antibiotics-08-00129],[@B12-antibiotics-08-00129],[@B13-antibiotics-08-00129]\]. Based on their resistance levels and clinical significance, the so-called "ESKAPE" pathogens ([Table 2](#antibiotics-08-00129-t002){ref-type="table"}) receive the utmost attention when it comes to the development of novel antimicrobials \[[@B17-antibiotics-08-00129],[@B18-antibiotics-08-00129],[@B19-antibiotics-08-00129],[@B20-antibiotics-08-00129],[@B21-antibiotics-08-00129]\]. This was further highlighted after the World Health Organization declared these microorganisms as priority pathogens for pharmaceutical companies \[[@B22-antibiotics-08-00129]\].

One of the main driving forces behind the development of antibacterial drug resistance is the misuse and overuse of these drugs, both in human medicine and in agriculture \[[@B1-antibiotics-08-00129],[@B2-antibiotics-08-00129],[@B3-antibiotics-08-00129]\]. Thus, programs and interventions aiming at optimizing the use of antimicrobial drugs (such as implementation of policies and guidelines, drug utilization reports, point prevalence surveys, both locally and internationally), collectively termed "antimicrobial stewardship", have received substantial attention \[[@B23-antibiotics-08-00129]\]. Antimicrobial stewardship includes decisions like the selection of the dose and duration of the most appropriate antimicrobial(s) for the patient with limited or no side effects, ensuring minimal impact on local resistance levels, ensuring their availability and efficacy for the future \[[@B24-antibiotics-08-00129]\]. In addition, the implementation of rapid diagnostic techniques in clinical microbiology laboratories (diagnostic stewardship) to aid the choice of drug therapy is another emerging facet of antimicrobial stewardship \[[@B25-antibiotics-08-00129]\]. This is also highlighted in scientific research; while in 2008, there were only *n* = 45 articles on this topic, in 2018, a nearly twenty-fold increase was observed (*n* = 804). To attain changes clinical practice, the appropriate attitude of healthcare professionals and their continuous professional development is of utmost importance \[[@B26-antibiotics-08-00129],[@B27-antibiotics-08-00129]\].

Considering the importance of antibiotic resistance and its effects on the QoL of patients and on the state of healthcare infrastructures as a whole, it is our pleasure to co-edit the Special Issue in *Antibiotics*, termed "Antibiotic Resistance: From the Bench to Patients". The Special Issue contains excellent quality research articles and comprehensive review papers on the epidemiology of various MDR pathogens worldwide, novel diagnostic and point-of-care (POCT) tests, interventional studies on antimicrobial drug utilization and pharmaco-epidemiological studies. In addition, the Special Issue welcomes reports on the knowledge, attitude, and practice of healthcare professionals (nurses, doctors, pharmacists, etc.) and patients regarding antibiotics and antibiotic resistance.
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###### 

Antibiotics recently approved by the Food and Drug Administration (FDA) and/or European Medicines Agency (EMA).

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Active Pharmaceutical Ingredient   Trade Name              Class/Comments
  ---------------------------------- ----------------------- -------------------------------------------------------------------------------------------
  Doripenem                          Doribax ^™^ (US)\       Carbapenem
                                     Finibax ^™^ (EU)        

  Ceftaroline fosamil                Teflaro ^™^ (US)\       Cephalosporin
                                     Zinforo^™^ (EU)         

  Ceftobiprole medocaril             Zevtera^™^(US)\         Cephalosporin
                                     Mabelio^™^ (EU)         

  Ceftolozane/tazobactam             Zerbaxa ^™^ (US/EU)     Combination antibiotic: cephalosporin/β-lactamase inhibitor

  Ceftazidime/avibactam              Avycaz^™^ (US/EU)       Combination antibiotic: cephalosporin/β-lactamase inhibitor

  Meropenem/vaborbactam              Vabomere^™^ (US)\       Combination antibiotic: carbapenem/β-lactamase inhibitor
                                     Carbavance^™^ (EU)      

  Imipenem/cilastatin/relebactam     Recarbrio ^™^ (US/EU)   Combination antibiotic: carbapenem/renal dehydropeptidase inhibitor/β-lactamase inhibitor

  Telavancin                         Vibativ^™^ (US)         Derivatives of either vancomycin or lipoglycopeptide

  Dalbavancin                        Dalvance^™^ (US)\       Derivatives of either vancomycin or lipoglycopeptide
                                     Xydalba^™^ (EU)         

  Oritavancin                        Orbactiv^™^ (US/EU)     Derivatives of either vancomycin or lipoglycopeptide

  Eravacycline                       Xerava^™^ (US/EU)       Tetracycline derivatives

  Sarecycline                        Seysara^™^ (US)         Tetracycline derivatives

  Omadacycline                       Nuzyra^™^ (US)          Tetracycline derivatives

  Bedaquiline,                       Sirturo^™^ (US/EU)      Diarylquinoline (DARQ)

  Tedizolid                          Sivextro ^™^ (US/EU)    Oxazolidinone

  Delafloxacin meglumine             Baxdela^™^ (US)         Fluoroquinolone

  Plazomicin                         Zemdri ^™^ (US)         Next-generation aminoglycoside (neoglycoside)

  Lefamulin                          Xenleta^™^ (US)         Pleuromutilin
  ------------------------------------------------------------------------------------------------------------------------------------------------------

US: Trade name in the United States; EU: trade name in the member states of the European Union.

antibiotics-08-00129-t002_Table 2

###### 

Current list of ESKAPE pathogens.

  ----------------------------------
  Pathogens
  ----------------------------------
  *Enterococcus faecium*

  *Staphylococcus aureus*\
  *(Stenotrophomonas maltophilia)*

  *Klebsiella pneumoniae*\
  *(Clostridioides difficile)*

  *Acinetobacter* spp.

  *Pseudomonas aeruginosa*

  *Enterobacter* spp.\
  (members of *Enterobacterales*)
  ----------------------------------
